| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— |
| 20 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— |
| 05 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
—Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership— |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
—Total Company Revenues of $425.5 Million for the Second Quarter of 2026— |
| 16 Jul 2026 |
8-K: Regulation FD Disclosure
July 16, 2026 12-Month Results from Ongoing Open-Label Extension Study of TPIP in PAH Patients TPIP: treprostinil palmitil inhalation powder | PAH: pulmonary arterial hypertension |
| 15 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The annual meeting of shareholders of Insmed Incorporated (the “Company”) was held on May 13, 2026 (the “Annual Meeting”). Set forth below are the voting results for each of the proposals submitted to a vote of the Company’s shareholders... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— |
| 07 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— |
| 23 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease |
| 19 Feb 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
—Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million— |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure
— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— |
| 17 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— |
| 18 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
—BRINSUPRI™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Japan— |
| 12 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— |
| 13 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
As representatives (the “Representatives”) of the several Underwriters |
| 10 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
June 10, 2025 Topline Results of Phase 2b Study of TPIP in PAH Patients TPIP: Treprostinil Palmitil Inhalation Powder | PAH: pulmonary arterial hypertension |
| 06 Jun 2025 |
8-K: Other Events
On June 6, 2025 (the “Redemption Date”), Insmed Incorporated (the “Company”) completed its previously announced redemption of all of the aggregate principal amount outstanding of its 0.75% Convertible Senior Notes due 2028 (the “Notes”).... |
| 16 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On May 15, 2025, at the annual meeting of shareholders of Insmed Incorporated (the “Company” and the “Annual Meeting”), the Company’s shareholders approved Amendment No. 2 to the Insmed Incorporated Amended and Restated 2019 Incentive Pl... |
Loading...